MA50056A - Procédés de traitement de tumeur - Google Patents

Procédés de traitement de tumeur

Info

Publication number
MA50056A
MA50056A MA050056A MA50056A MA50056A MA 50056 A MA50056 A MA 50056A MA 050056 A MA050056 A MA 050056A MA 50056 A MA50056 A MA 50056A MA 50056 A MA50056 A MA 50056A
Authority
MA
Morocco
Prior art keywords
treatment processes
tumor treatment
tumor
processes
treatment
Prior art date
Application number
MA050056A
Other languages
English (en)
Inventor
Prabhu Seshaiyer Bhagavatheeswaran
Nicholas Allan John Botwood
Han Chang
Yali Fu
William J Geese
George A Green Iv
Diane Healey
Sabine Maier
Faith E Nathan
Abderrahim Oukessou
Giovanni Selvaggi
Joseph Daniel Szustakowski
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA50056A publication Critical patent/MA50056A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
MA050056A 2017-03-31 2018-03-30 Procédés de traitement de tumeur MA50056A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479817P 2017-03-31 2017-03-31
US201762582146P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
MA50056A true MA50056A (fr) 2020-02-05

Family

ID=62067782

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050056A MA50056A (fr) 2017-03-31 2018-03-30 Procédés de traitement de tumeur

Country Status (13)

Country Link
US (3) US20210101980A1 (fr)
EP (1) EP3601355A1 (fr)
JP (2) JP7458188B2 (fr)
KR (2) KR102775647B1 (fr)
CN (1) CN110494450A (fr)
AU (2) AU2018243754B2 (fr)
BR (1) BR112019019795A2 (fr)
CA (1) CA3058175A1 (fr)
IL (3) IL269026B2 (fr)
MA (1) MA50056A (fr)
MX (2) MX2019010958A (fr)
SG (2) SG11201908396PA (fr)
WO (1) WO2018183928A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
BR112020018539A2 (pt) * 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
EP3857555A4 (fr) * 2018-10-17 2022-12-21 Tempus Labs Systèmes et procédés de recherche et de traitement du cancer basés sur des données
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
US12479917B2 (en) * 2018-10-23 2025-11-25 Bristol-Myers Squibb Company Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
JP7623281B2 (ja) * 2018-11-15 2025-01-28 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド 免疫療法で治療されたがん患者の応答の予測を改善する方法
EP3893932A4 (fr) * 2018-12-12 2022-09-07 Medimmune, LLC Charge de mutation de tumeur basée sur le sang permettant de prédire la survie globale dans le cancer du poumon non à petites cellules
EP3899951A1 (fr) * 2018-12-23 2021-10-27 F. Hoffmann-La Roche AG Classification de tumeur basée sur une charge mutationnelle tumorale prédite
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN113891748A (zh) * 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
GB201904555D0 (en) * 2019-04-01 2019-05-15 Univ Manchester Biomarkers and uses thereof
CN110229894B (zh) * 2019-05-21 2020-09-08 武汉大学 一种基因组合及其在制备预测接受免疫检查点抑制剂治疗患者预后的试剂中的应用
EP3982954A4 (fr) 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York Inhibiteurs de nt5c2 pour le traitement de la leucémie lymphoblastique aiguë résistante à la chimiothérapie
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
EP4013494A1 (fr) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Variants du récepteur 1 de la stimulation des macrophages (mst1r) et leurs utilisations
AU2020364081A1 (en) * 2019-10-09 2022-05-26 The University Of North Carolina At Chapel Hill DNA copy number alterations (CNAs) to determine cancer phenotypes
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途
CN111269979A (zh) * 2020-02-06 2020-06-12 至本医疗科技（上海）有限公司 Arid1b基因变异在预测肺腺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN110923329B (zh) * 2020-02-06 2020-05-12 至本医疗科技（上海）有限公司 Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
EP4153783A1 (fr) * 2020-05-21 2023-03-29 Astrazeneca AB Charge de mutation de tumeur associée à la sensibilité à l'immunothérapie dans un carcinome urothélial localement avancé ou métastatique
TWI788188B (zh) * 2020-06-09 2022-12-21 南韓商阿特根公司 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
EP4194551A4 (fr) 2020-08-07 2024-08-28 Alteogen, Inc. Procédé de production d'hyaluronidase recombinant
CN112143810B (zh) * 2020-09-29 2023-11-21 南方医科大学中西医结合医院 一组用于预测癌症免疫治疗效果的基因标志物及其应用
EP4267129A1 (fr) * 2020-12-22 2023-11-01 IFM Due, Inc. Méthodes de traitement du cancer
WO2022135402A1 (fr) * 2020-12-24 2022-06-30 信达生物制药(苏州)有限公司 Utilisation d'un biomarqueur pd-l1 et/ou cmh-2 dans la prédiction de l'efficacité thérapeutique chez des patients atteints d'un cancer du poumon
KR102371762B1 (ko) * 2020-12-29 2022-03-07 중앙대학교 산학협력단 Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도
CN113005146A (zh) * 2021-03-10 2021-06-22 香港理工大学深圳研究院 一种重组质粒及其构建方法、重组影像系统与应用
US20240254230A1 (en) * 2021-03-19 2024-08-01 Shanghai Junshi Biosciences Co., Ltd. Method of treating urothelial carcinoma
WO2022245692A1 (fr) * 2021-05-19 2022-11-24 Merck Sharp & Dohme Llc Traitement de patients cancéreux présentant une modification du biomarqueur setd2 avec un antagoniste de pd-1
JP7806990B2 (ja) * 2021-08-10 2026-01-27 国立大学法人 新潟大学 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法
US20240393339A1 (en) * 2021-09-24 2024-11-28 The Regents Of The University Of California Methods to predict the efficacy of neoadjuvant anti-pd-1 therapy in resectable oral-cavity squamous cell carcinoma and target post-surgical relapses
CN113981080A (zh) * 2021-10-15 2022-01-28 复旦大学附属肿瘤医院 晚期三阴性乳腺癌铂类治疗敏感性的预测指标生成分析方法
US20250019770A1 (en) * 2021-11-12 2025-01-16 Foundation Medicine, Inc. Circulating tumor dna fraction and uses thereof
CN114213542B (zh) * 2021-12-24 2023-06-23 郑州大学第三附属医院(河南省妇幼保健院) Cps-i抗体及其用途
EP4476368A4 (fr) * 2022-02-11 2026-03-04 Found Medicine Inc Utilisation d'une charge mutationnelle tumorale en tant que biomarqueur prédictif pour un inhibiteur de point de contrôle immunitaire par rapport à l'efficacité de chimiothérapie dans le traitement du cancer
WO2023209035A1 (fr) * 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Procédés et compositions pour prédire une réponse à une thérapie anticancéreuse
CN114736967B (zh) * 2022-05-07 2024-06-11 北京大学肿瘤医院 预测免疫检查点抑制剂疗法原发耐药的标志物及方法
EP4310197A1 (fr) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Procédé pour identifier des patients atteints de cancer du poumon pour un traitement combiné d'immunothérapie et de chimiothérapie
EP4361288A1 (fr) * 2022-10-25 2024-05-01 Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) Immunothérapie personnalisée dans le carcinome rénal
CN115449555B (zh) * 2022-10-26 2023-10-13 山东大学 Adgra2作为乳腺癌化疗疗效和预后评价生物标志物的应用
CN116449009A (zh) * 2023-01-30 2023-07-18 上海秤信生物科技有限公司 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物
WO2024203348A1 (fr) * 2023-03-31 2024-10-03 ソニーグループ株式会社 Procédé d'analyse de tumeurs, système d'analyse de tumeurs et procédé de génération de données d'analyse de tumeurs

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
ES2466715T3 (es) 1999-06-25 2014-06-11 Immunogen, Inc. Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
WO2001014557A1 (fr) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, recepteur de b7-4, et son utilisation
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1261376A1 (fr) 2000-01-27 2002-12-04 Genetics Institute, LLC Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations
WO2004010947A2 (fr) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Anticorps humanises contre le 4-1bb humain
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
KR101420344B1 (ko) 2003-07-02 2014-07-16 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
EP2292264A3 (fr) 2003-07-24 2012-12-19 Innate Pharma Procédés et compositions pour augmenter l'efficacité des anticorps thérapeutiques en utilisant des composés de potentialisation de cellules NK
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
WO2006072625A2 (fr) 2005-01-06 2006-07-13 Novo Nordisk A/S Procedes et traitements combines anti-kir
SI1836225T1 (sl) 2005-01-06 2012-06-29 Novo Nordisk As Kir vezujoäśa sredstva in postopki za njihovo rabo
WO2006105021A2 (fr) 2005-03-25 2006-10-05 Tolerrx, Inc. Molecules de liaison gitr et leurs utilisations
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5419067B2 (ja) 2005-10-14 2014-02-19 イナート・ファルマ・ソシエテ・アノニム 増殖性障害を処置するための組成物および方法
CA2647282A1 (fr) 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
CN101578113B (zh) 2007-01-11 2015-04-22 诺和诺德公司 抗-kir抗体、制剂及其应用
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2693677C (fr) 2007-07-12 2018-02-13 Tolerx, Inc. Therapies combinees utilisant des molecules de liaison au gitr
CA2700860C (fr) 2007-10-01 2016-07-19 Jonathan A. Terrett Anticorps humains qui se lient a la mesotheline, et utilisations de ceux-ci
TW200938224A (en) 2007-11-30 2009-09-16 Medarex Inc Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
MX339621B (es) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Anticuerpos que se unen a cd27 humano y uso de los mismos.
CA2818684C (fr) 2010-11-22 2023-02-21 Innate Pharma Sa Traitements modulant les cellules tueuses naturelles et methodes de traitement d'hemopathies malignes
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
EP2760471B9 (fr) 2011-09-30 2017-07-19 Dana-Farber Cancer Institute, Inc. Peptides thérapeutiques
AU2012335553B2 (en) 2011-11-09 2017-09-21 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-CXCR4 antibody
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR102130865B1 (ko) 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
KR20250091304A (ko) 2013-03-15 2025-06-20 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CA2907249A1 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides therapeutiques
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
EP3090066A4 (fr) * 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à l'immunothérapie
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US20170313775A1 (en) * 2014-11-13 2017-11-02 The Johns Hopkins University Checkpoint Blockade and Microsatellite Instability
MA40737A (fr) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CA3175979A1 (fr) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anticorps anti-pd-1
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
ES2861352T3 (es) * 2015-04-28 2021-10-06 Bristol Myers Squibb Co Tratamiento del melanoma positivo para PD-L1 utilizando un anticuerpo anti-PD-1
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
WO2017020291A1 (fr) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Nouveaux anticorps anti-pd-l1
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
MY187739A (en) 2015-08-11 2021-10-18 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
WO2017024515A1 (fr) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Nouveaux anticorps anti-pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CA3008287A1 (fr) 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukine-10 utilisee dans la production de lymphocytes t cd8+ specifiques a un antigene et methodes d'utilisation de celle-ci
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (fr) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
WO2017151517A1 (fr) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Méthodes de traitement du cancer
JP7027401B2 (ja) 2016-07-14 2022-03-01 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
IL265759B2 (en) * 2016-10-06 2025-10-01 Genentech Inc Therapeutic and diagnostic methods for cancer
KR20200064132A (ko) * 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법

Also Published As

Publication number Publication date
MX2024007719A (es) 2024-09-10
EP3601355A1 (fr) 2020-02-05
JP2024096701A (ja) 2024-07-17
IL325195A (en) 2026-02-01
SG10202110594UA (en) 2021-11-29
KR102775647B1 (ko) 2025-03-06
CN110494450A (zh) 2019-11-22
BR112019019795A2 (pt) 2020-04-22
US20250059610A1 (en) 2025-02-20
US20230295737A1 (en) 2023-09-21
IL313939B1 (en) 2026-01-01
SG11201908396PA (en) 2019-10-30
US20210101980A1 (en) 2021-04-08
WO2018183928A1 (fr) 2018-10-04
AU2018243754A1 (en) 2019-10-17
IL269026B2 (en) 2024-12-01
JP7458188B2 (ja) 2024-03-29
IL269026B1 (en) 2024-08-01
IL269026A (en) 2019-10-31
AU2025205056A1 (en) 2025-07-24
IL313939A (en) 2024-08-01
CA3058175A1 (fr) 2018-10-04
MX2019010958A (es) 2019-10-17
JP2020512982A (ja) 2020-04-30
KR20190133213A (ko) 2019-12-02
AU2018243754B2 (en) 2025-04-10
KR20250036268A (ko) 2025-03-13

Similar Documents

Publication Publication Date Title
MA50056A (fr) Procédés de traitement de tumeur
EP3426250A4 (fr) Procédés de traitement
EP3601536A4 (fr) Procédés de traitement
EP3294065A4 (fr) Procédés de traitement du cancer
EP3488001A4 (fr) Traitement du cancer
EP3388004A4 (fr) Instrument de traitement
EP3399861A4 (fr) Procédés de traitement du cancer par interféron
EP3448263A4 (fr) Traitement électrothérapeutique
EP3409744A4 (fr) Agent de traitement de surface
EP3489759A4 (fr) Cartouche de traitement
MA47408A (fr) Traitement du cancer
PL3197456T3 (pl) Leczenie nowotworów
EP3431566A4 (fr) Agent de traitement de surface
EP3606531A4 (fr) Méthodes de traitement du cancer
EP3375108A4 (fr) Traitement dewlan
EP3442946A4 (fr) Procédés de traitement du cancer
EP3705545A4 (fr) Composition de traitement de surface
EP3914235A4 (fr) Procédés de traitement de la dépendance
EP3525703A4 (fr) Dispositifs et procédés de traitement
MA52627A (fr) Traitement du cancer
DK3576740T3 (da) Cancerbehandling
EP3733175A4 (fr) Traitement du cancer
EP3684342A4 (fr) Procédé de traitement
EP3619170A4 (fr) Procédé de traitement de l'eau
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline